As the U.S. population ages, there is growing awareness of PVD and deep vein thrombosis (DVT) as potentially significant public health concerns. In their search for effective treatments for these conditions, interventional cardiologists, vascular surgeons and interventional radiologists are devising innovative ways to combine drug and device therapies. The AngioJet System is readily adaptable to this type of combination therapy. In fact, Possis has plans to support clinical and investigational trials designed to explore the use of the AngioJet System in combination with lytic drugs for accelerated treatment of symptomatic iliofemoral or femoral DVT. Possis Medical’s market development efforts for combination therapies will include efforts to improve the reimbursement patterns for these innovative treatments. As we step toward the future, Possis is also investing more in post-market clinical studies to gather additional clinical data supporting both peripheral and coronary use of the AngioJet technology. The AJILE study (of AngioJet for Ischemic Arterial Occlusions in Lower Extremities) of 42 patients is now complete, and we have accelerated enrollment for the AiMI (AngioJet in Myocardial Infarction) study with enrollment currently at more than 360 patients. This study explores the use of AngioJet Rheolytic thrombectomy in patients undergoing primary angioplasty for acute myocardial infarction or heart attack.